A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer:: clinical and dosimetric factors analysis

被引:167
作者
Claude, L
Pérol, D
Ginestet, C
Falchero, L
Arpin, D
Vincent, M
Martel, I
Hominal, S
Cordier, JF
Carrie, C
机构
[1] Ctr Leon Berard, Dept Radiat Oncol, F-69373 Lyon 08, France
[2] Ctr Leon Berard, UBET, Dept Publ Hlth, F-69373 Lyon, France
[3] Ctr Hosp, Dept Resp Med, Villefranche Sur Mer, France
[4] Hosp Chanaux, Dept Resp Med, Macon, France
[5] Hop St Joseph, Dept Resp Med, Lyon, France
[6] Ctr Hosp Croix Rousse, Dept Resp Med, Lyon, France
[7] Hop Louis Pradel, Dept Resp Med, Lyon, France
关键词
non-small cell lung cancer; conformal radiation therapy; dose-volume-histogram; radiation pneumonitis;
D O I
10.1016/j.radonc.2004.02.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and purpose: Clinical and dosimetric prognostic factors for radiation pneumonitis (RP) have been reported after three-dimensional conformal radiotherapy (3D-CRT) in patients with non-small cell lung cancer (NSCLC). Patients and methods: Ninety-six patients who received 3D-CRT for stage IA to IIIB NSCLC were evaluated prospectively. Surgery was performed before radiation in 51 % of the patients (n = 49). RP was diagnosed six-eight weeks after 3D-CRT using the Lent-Solna classification. Factors evaluated included treatment factors such as total mean lung dose (MLD), and dose-volume histogram (DVH) thresholds for several radiation dose steps. These thresholds were originally determined from the median of the irradiated lung volume at each step. Results: Six patients could not be evaluated for RP six weeks after 3D-CRT. Of the 90 remaining patients, 40 (44%) had RP (i.e. grade greater than or equal to 1) at 6 weeks, including 7 patients (7.8%) with severe RP (grade greater than or equal to 2). Regarding the whole toxicity (grade greater than or equal to 1), age ( greater than or equal to 60 years), MLD, V20 and V30 were significantly related to RP. DVH thresholds determined for radiation doses from 20 to 40 Gy were also predictive of RP. Considering only severe RP (grade greater than or equal to 2), only MLD, V20 and V30 remained associated with increased acute pulmonary toxicity. Conclusions: In this study, dosimetric factors (MLD, V20, V30) and age ( greater than or equal to60 years) were predictive of RP regarding the whole pulmonary toxicity (grade greater than or equal to 1). In addition, thresholds from 20 to 40 Gy, based on a stratification according to the median of the percentage of irradiated lung volume, were also predictive factors. They may, therefore, help discriminate patients at high and low risk for RP. However, only MLD, V20 and V30 remained associated with severe RP (grade : 2), probably due to the small number of severe events in our series. (C) 2004 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:175 / 181
页数:7
相关论文
共 25 条
  • [1] [Anonymous], 1995, RADIOTHER ONCOL, V35, P17
  • [2] [Anonymous], 1994, 50 ICRU
  • [3] Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer
    Armstrong, J
    Raben, A
    Zelefsky, M
    Burt, M
    Leibel, S
    Burman, C
    Kutcher, G
    Harrison, L
    Hahn, C
    Ginsberg, R
    Rusch, V
    Kris, M
    Fuks, Z
    [J]. RADIOTHERAPY AND ONCOLOGY, 1997, 44 (01) : 17 - 22
  • [4] THE INFLUENCE OF FIELD SIZE AND OTHER TREATMENT FACTORS ON PULMONARY TOXICITY FOLLOWING HYPERFRACTIONATED IRRADIATION FOR INOPERABLE NONSMALL CELL LUNG-CANCER (NSCLC) - ANALYSIS OF A RADIATION-THERAPY ONCOLOGY GROUP (RTOG) PROTOCOL
    BYHARDT, RW
    MARTIN, L
    PAJAK, TF
    SHIN, KH
    EMAMI, B
    COX, JD
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1993, 27 (03): : 537 - 544
  • [5] TOXICITY CRITERIA OF THE RADIATION-THERAPY ONCOLOGY GROUP (RTOG) AND THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER (EORTC)
    COX, JD
    STETZ, J
    PAJAK, TF
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 31 (05): : 1341 - 1346
  • [6] A RANDOMIZED PHASE-I/II TRIAL OF HYPERFRACTIONATED RADIATION-THERAPY WITH TOTAL DOSES OF 60.0 GY TO 79.2 GY - POSSIBLE SURVIVAL BENEFIT WITH GREATER-THAN-OR-EQUAL-TO 69.6 GY IN FAVORABLE PATIENTS WITH RADIATION-THERAPY ONCOLOGY GROUP STAGE-III NON-SMALL-CELL LUNG-CARCINOMA - REPORT OF RADIATION-THERAPY ONCOLOGY GROUP 83-11
    COX, JD
    AZARNIA, N
    BYHARDT, RW
    SHIN, KH
    EMAMI, B
    PAJAK, TF
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (09) : 1543 - 1555
  • [7] Radiation pneumonitis after breast cancer irradiation:: Analysis of the complication probability using the relative seriality model
    Gagliardi, G
    Bjöhle, J
    Lax, I
    Ottolenghi, A
    Eriksson, F
    Liedberg, A
    Lind, P
    Rutqvist, LE
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2000, 46 (02): : 373 - 381
  • [8] Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC)
    Graham, MV
    Purdy, JA
    Emami, B
    Harms, W
    Bosch, W
    Lockett, MA
    Perez, CA
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1999, 45 (02): : 323 - 329
  • [9] Radiation-induced pulmonary toxicity: A dose-volume histogram analysis in 201 patients with lung cancer
    Hernando, ML
    Marks, LB
    Bentel, GC
    Zhou, SM
    Hollis, D
    Das, SK
    Fan, M
    Munley, MT
    Shafman, TD
    Anscher, MS
    Lind, PA
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2001, 51 (03): : 650 - 659
  • [10] WHY DO SO MANY PROGNOSTIC FACTORS FAIL TO PAN OUT
    HILSENBECK, SG
    CLARK, GM
    MCGUIRE, WL
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 1992, 22 (03) : 197 - 206